Phase 3 retatrutide obesity trial data showing up to 30.3% weight loss bolsters LLY’s GLP-1 franchise leadership, analysts say.
Truist maintained a Buy rating on Eli Lilly (LLY) with a $1,281 price target after the company reported Phase 3 retatrutide clinical trial data. Patients on the 12 mg dose achieved 28.3% weight loss at 80 weeks and 30.3% at 104 weeks, setting a new benchmark for anti-obesity medications.
Wolfe Research also kept an Outperform rating on LLY with a $1,350 target, citing the data as further evidence of the company’s leadership in obesity therapeutics. Both firms highlighted retatrutide’s potential to address unmet needs in patients inadequately served by existing incretin therapies.
Eli Lilly’s GLP-1 franchise strengthens its position in diabetes and obesity markets, with the latest trial results supporting future approval and commercial prospects.